Adalimumab induces and maintains remission in severe, resistant paediatric Crohn disease.
Hadziselimovic
Faruk
F
Department of Pediatric Gastroenterology and Pediatric FMH, Kindertagesklinik Liestal, Liestal, Switzerland. faruk@magnet.ch
D000068879:Adalimumab; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D002675:Child, Preschool; D003424:Crohn Disease / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D004750:Enteral Nutrition; D006801:Humans; D008297:Male; D017511:Pyoderma Gangrenosum / Q000188:drug therapy* / Q000473:pathology; D012074:Remission Induction; D016896:Treatment Outcome; D015430:Weight Gain
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068879:Adalimumab